Got 50k at .035 so not quite. lol

GAP Is that news I smell?

Dave was attending his biker club's monthly meeting and had just told them he couldn't make the camping trip scheduled for the next day because his wife wouldn't let him go.

After listening to the jeers and other derisive remarks from his fellow biker buddies Dave left to go back home to his wife.

When Dave's friends started arriving to set up camp the next day, who should be there but Dave sitting in front of his bike, tent up, beer in hand, camp oven roast stewing away in a hot bed of coals.

"How did ya talk your wife into letting you go Dave?" "I didn't have to" was Dave's reply.

"When I left the meeting I went home and slumped down in my chair with a beer to drown my sorrows. Then my wife Snuck up behind me and covered my eyes and said, 'Surprise'!"

When I peeled her hands back she was standing there in a beautiful see-through negligee and she said, "Carry me into the bedroom, tie me to the bed and you can do whatever you want."

So here I am!

lol

And right after that it hit .19

Now that's really odd!

Forget EVG... EDG is the real one! Breakout!!!!!!!!!!!!!!!

EDG is an easy double on the pump and you know its coming.

Endurance Gold finishes mapping, sampling in Wyoming

2009-06-25 17:40 ET - News Release

Mr. Duncan McIvor reports

ENDURANCE IDENTIFIES GOLD MINERALIZATION ON 100% OWNED GOLD PROPERTIES IN RATTLESNAKE HILLS AREA, NATRONA COUNTY, WYOMING

Endurance Gold Corp., through its 100-per-cent-owned United States subsidiary, Endurance Resources Inc., has completed an initial reconnaissance mapping and sampling program on five of six of its 100-per-cent-owned gold properties. The Endurance properties are located immediately adjacent to the Evolving Gold property and discovery located in the Rattlesnake Hills area of central Wyoming. Endurance acquired the small but strategic property position through staking earlier this year (see press release dated Feb. 27, 2009, as reported in Stockwatch). Gold values up to 0.66 gram per tonne gold have been returned from a geological environment identical to the adjacent Evolving Gold discovery.

The five properties are located between 1.7 and four kilometres from the North Stock target area on the Evolving Gold ground, where a 15,000-metre diamond drilling program is under way. Previously reported drill intercepts by Evolving Gold on the North Stock target include 2.92 grams per tonne gold over 146.3 metres (Hole RSC-003), 2.74 grams per tonne gold over 131.1 metres (Hole RSC-007) and 0.9 gram per tonne gold over a composite interval of 359.6 metres (Hole RSC-012). The sixth Endurance property is located approximately eight kilometres west of the Evolving Gold discovery and was inaccessible due to winter washouts.

Good news for sure!

Lets see if we can break .20 tomorrow.

Oh good. He'll be able to afford to join us at Northern Bear then, for a celebratory round of 18 when we cash in.

Investors see value in PharmaGap. Await cancer test results.


By Armando Duke

(AXcess News) Houston - Investors were lining up in PharmaGap (TSX-V: GAP; OTC: PHRGF.PK) over the past several weeks in advance of testing results of its drug compound PhG-alpha-1 for the treatment of cancer which is in preclinical development. Tests are being conducted both in Canada and the US.

Ottawa-based PharmaGap announced in early May 2009 that the National Cancer Institute in Bethesda Maryland was conducting tumor cell panel tests on 60 human cancer cell lines. Additional testing on the effect of PhG-alpha-1 on cancer cell growth rate, mobility and invasion characteristics, using a panel of nine ovarian cancer cell lines is also being conducted at the Ottawa Hospital Research Institute (OHRI), which was announced the day before the NCI tests. Of the OHRI cell lines being tested, two are also included in the 60 cell line panel used in the NCI tests.

Robert McInnis, President of PharmaGap, had revealed in that May announcement that the Company had contracted with CS Bio of Menlo Park California to produce its cancer drug, PhG-alpha-1, a key step in meeting FDA Health Canada guidelines in approving drugs for human testing. McInnis was quoted in that release as saying, "We are also very pleased to have developed a relationship with CS Bio as a commercial partner for larger scale drug production going forward."

PharmaGap was featured in a syndicated AXcess News story on May 17, having announced later that day the completion of an $860,000 private placement. In that news it was noted that PharmaGap was one of only five companies Canada's National Research Council (NRC) had invested in, a practice AXcess News criticized the Obama administration over for not considering similar programs as part of its healthcare reform plan.

The following week, PharmaGap announced a second round of financing with NRC to the tune of $215,000, placing the government-backed National Research Council's stake in the biotechnology company at 3.2 percent.

At the time of that announcement, McInnis was quoted as saying, "We are pleased that the NRC recognizes the value potential in our Company, and appreciate its continued support as a valued partner."

Were you playing catch up today?

GAP must be the best kept secret in the world right now...

Galore starts drilling 3,500 m at Dos Santos


2009-07-09 09:37 ET - News Release

Mr. Michael Byrne reports

GALORE'S DOS SANTOS DRILL PROGRAM UNDERWAY

Galore Resources Inc.'s target date for the commencement of a 3,500-metre reverse-circulation drill program on its Dos Santos gold project in northern Zacatecas state, Mexico, has been met. Drilling on the northern claims of Galore's 14,000-hectare property commenced on July 1.

"After a year of preliminary exploration work on Dos Santos, we are excited to be drilling on this highly prospective project located in such an active and historic mining district," said president Michael Byrne. The Dos Santos project generated encouraging results earlier this year in a trenching program that yielded values up to 208 grams of gold per tonne over 0.5 metre.

The 100-per-cent-owned property is in the historic Concepcion del Oro mining district, 35 kilometres southeast of Goldcorp's massive Penasquito mine, and lies adjacent to the northern boundary of Canplats's recent Camino Rojo gold discovery.

ALS Laboratory Group has opened a new assay sample preparation facility in Zacatecas that will assist the company in generating timely and cost-effective assay results. The results are expected to be received throughout and following the course of the six-week drill program.

The Dos Santos exploration program is managed by Octavio Gonzalez, Galore's vice-president of exploration for Mexico. Uwe Schmidt, PGeo, vice-president, exploration, and Galore's qualified person as defined by Canada's National Instrument 43-101, is responsible for supervising the Dos Santos program and has verified the technical data in this release.

We seek Safe Harbor.

1st annual eh? Maybe we should make Tackler drive a bit further next time.

So, why'd you give it up?

Screw em. I'm going to start making my own tax free brew.

Dumb move. Didn't like the hike and I don't like the reversal much either. Make up your mind Eddy!

It looks like more of a long term play but I don't own it. Just posting it here so I don't forget about it.

Jaguar Mining: Born to Perform (Link has graphs)
by: Hyperinflation July 01, 2009 | about: JAG

Yes that's a jaguar, but not the car. Rather, it's the best in class emerging Junior Miner with a unique set of attributes among its peers. I think of Jaguar Mining (JAG) as a junior hybrid of Agnico-Eagle (AGM) (due to the extraordinary production growth over the next 3 years or so) and Yamana Gold (AUY) (due to the location of their flagship mines in South America, not to mention their low cash cost profile). Jaguar has been around for a while but instead of the explosive growth it has set itself up for (2009-2013), it has displayed remarkable execution growing production at a consistent steady rate. Before I go into the details of why this is such a value among the junior mining industry, I will give a brief overview of its current mines and those which will come-on line in the not too distant future.

Mines in Operation:

The largest mine currently producing is Turmalina which produced about 19,000 oz in Q1 with cash costs below $350/oz. A ramp up in production is expected in its entire mining portfolio, so this will increase quarter after quarter.
Coming in at a close second is the Paciencia mine which came on-line Q2 of 2008. It is expected to past Turmalina in 2010 in regards to production. It currently has much higher cash costs of $490/oz, but that will decline to around $400-$425/oz next year.
The Sabara mine is the last currently producing mine, but relatively small to the first two. It also has high cash costs which are expected to moderate, but will still have the highest average cost per ounce of all their mines. It was also not in operation in the first quarter due to weather.
Finally, its Caete Mine will be a nice addition to the portfolio as it begins production in about a year (possibly Q3/2010).
It is nice to find an emerging miner that doesn't have all its eggs in one basket. Jaguar's Turmalina + Sabara make up about 1/3 of its NAV as well, and the other two mines account for another 1/3 give or take. It is very unique for a growing capital intensive company to have an extremely low debt of $70m and $55m in cash.



As mentioned previously, a meager 110k of production in 2008 will catapult to nearly 700k oz by 2014 assuming no additional reserves are found. A long term production growth rate of 35-40% is amazing on its own. But it also has low cash costs around $400-420/oz, and if you're in the inflation boat I'm in, this is extremely bullish for the company. I think gold will double during the next leg of the commodity bull market, mostly propelled by inflation (both in the U.S and around the world). If you aren't familiar with the term free cash flow, I will explain it very briefly.

Free cash flow is basically the real profit of the company to the shareholder, because in order for a company to keep operations going, a certain amount of capital has to be reinvested. That being said, because the value of any asset of the present value of all future cash flows, free cash flow is the real profit. It is calculated as Net Income (although I make sure no extraordinary items are mixed in) -+Depreciation (which was taken out as a non-cash charge) - Capital Expenditures (both increase in PPE and acquisitions if any occurred) - change in non-cash working capital (Non cash current assets in year T - current liabilities in year T).

Below is a chart of Jaguar's capital expenditures going forward:



These are extremely low reinvestment needs for such strong growth, the likes of which I have yet to come upon for a miner with similar attributes. In other words this means Jaguar is well capitalized, has strong long term growth and needing little reinvestment to support that growth making it a huge free cash flow machine. I think instead it will be bought.

Jaguar Valuation Model

Above is an open for editing link to a Valuation I made for Jaguar, so you can change the projected gold price around. It also includes a sensitivity analysis.

http://seekingalpha.com/article/146483-jaguar-mining-born-to-perform?source=email

I thought after the G2 you would have learned. lol

Looks like we might have some nice soft fairways by Friday if the weather forecast holds.

Nothing against Roloson, but his best years are behind him. I think the Oilers played it right, offering him a one year deal.

What a chump Heatley is, demands a trade and then doesn't waive his clause. It's probably a good thing we didn't get this whiner.

As sick as that sounds thats not bad money for a quality goaltender. Better than Roloson for 2 years and 5 million in my opinion. Time will tell.

The Bulin Wall is coming to E-Town!

I was in Ft Mac today. Missed the EC move. Still holding some from .18

#msg-39147889 Not sure why you bash IAE every chance you get.

I guess somebody at Canaccord wants out.

No debt left and now they are loaded with cash to drill and acquire new prospects. Looks like a win-win to me and the market likes it too.

GI Joe?

Need an accountant to figure that one out.

Played Riverside on Friday night and managed to get the G2 to work for a change. I'm looking forward to the next game.

IAE sure fell fast from .75

Whats up with that?

Soccer is such a great sport you know.

What's IDGAF ?

What do you think EC will do now? I'm looking for an entry.

This is worth reading...From a post last year:



EscapedLabRat0
6/6/2008 1:06:15 PM | | 278 reads | Post #23428071


I have just recently happened upon this bulletin board and have read many of the posts. Frankly, I'm astonished that few contributors seem to have done their homework on this company. As one with a scientific background, I have been a biotech investor for years. I can say that I have made money in biotech but rarely in other fields such as high tech and mining. I've had some tremendous winners. Having said that, biotech is extremely tricky to negotiate even for the well informed. This is not an area to tread blindly. Fortunes of many companies have changed over and over through the years. Take a look at several established Candian biotechs - Biomira, Isotechnica, Conjuchem, Thera Technologies, QLT and Neurochem just to name a few. These are all well-known biotechs that have seen their stock run to unbelievable highs, fall back to pennies, run up again, fall back again, run back up and so on and so on. Many, many average non scientific people have made a lot of money on these companies. NB. Getting in early is the way to go.

I've been following the Pharmagap story (along with others) for a while. I would not have touched GAP until the last little while. However, with today's news and the last 2-3 releases, the picture is starting to change and I think this is one of the best early stage companies in Canada right now. What I find impressive, is the following:

1. Management Team - they have a serious, well connected Chairman in Bryden (formerly Systemhouse, WorldHeart, Ottawa Senators). This man doesn't blink and he does not suffer fools lightly. He undoubtedly hired the top scientists in Canada to do his due diligence and advise him before taking on GAP. He did not abandon the company even when the stock was a nickel.
2. Science Team-they have founding scientists with excellent reputations internationally (see for yourself - do a citation search!)
3. History - The program came out of the National Research Council which most recently gave us the best vaccine in the world to treat meningococcal infections in humans worldwide and the first to be safely used in babies. This vaccine has made hundreds of millions of $.
4. Longevity - They've been around for at least 5 years and getting stronger as the news indicates.
5. Strength in Biology - The company is exploring a unique biology that may have huge ramifications not only in cancer but in other dieases and applications including drug delivery and combination therapies. They can stick to cancer and probably start licensing other applications to big pharma creating a potential revenue and royalty stream.
6. Chemistry - Chemistry is the lifeblood of the pharmaceutical industry. Other biotech companies may understand their biology niche but haven't found a lead molecule to take to the clinic. There are too many companies like that to count and I would never buy into these companies. However, GAP is not only making inroads to understanding the biology, they appear able to manipulate the biology. GAP has modelled the relevant proteins and has generated and tested in all likelihood many, many molecules until it found one that works particularly well. It now has a lead molecule to move into the clinic as a drug. So they have the biology and the chemistry. This is rare in a biotech.
7. Future Merger or Acquisition? They've got biology, they've got the modelling, they've got chemistry, they've got a molecule, once they have a successful clinical trial under their belt, they will be acquired by someone with very deep pockets.
8. International Stature - they have gone international. They have the best collaborators, including Sloan-Kettering, in cancer today.

A word on Sloan-Kettering. Everyone trying to develop a cancer treatment, be it vaccine or drug wants to work with Sloan-Kettering. However, you do not choose Sloan-Kettering...Sloan-Kettering chooses you. Sloan-Kettering is arguably the most esteemed cancer center in the U.S. today. The scientists are among the very best worldwide working in cancer. The center fields hundreds of potential projects and collaborations each year. They cannot possibly accept them all, but only a fraction of them. Sloan-Kettering has a reputation to uphold. They only pick the best scientists/companies with the best science and projects to work with. Sloan-Kettering picks the projects with the highest potential for success. They have picked Pharmagap and their sceintists to work with. Scientists, more than any one else, want to be winners and be associated with winners. This pretty much says everything we need to know at this stage of the company's growth and is enough for a knowledgable person to start accumulating the stock.

We got half a million on the bid so maybe somethings getting started.

Rumours started by some pumper on Stockhouse.

Who said anything about a promo?